Nurix Therapeutics Inc
NASDAQ:NRIX
| Market Cap (Intraday) | 679.08M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $9.32 |
| 50-Day MA | $10.72 |
| 200-Day MA | $13.85 |
Nurix Therapeutics Inc Stock, NASDAQ:NRIX
1700 Owens Street, Suite 205, San Francisco, California 94158
United States of America
Phone: +1.415.660.5320
Number of Employees: 286
Description
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rap�©, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.